Kiora Pharmaceuticals (KPRX) and Its Competitors Financial Comparison

Kiora Pharmaceuticals (NASDAQ:KPRX – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Kiora Pharmaceuticals to similar companies based on the strength of its valuation, institutional ownership, dividends, analyst recommendations, risk, profitability and earnings.

Profitability

This table compares Kiora Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Kiora Pharmaceuticals N/A -81.61% -55.29%
Kiora Pharmaceuticals Competitors -2,400.61% -215.91% -15.58%

Valuation and Earnings

This table compares Kiora Pharmaceuticals and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Kiora Pharmaceuticals $16.02 million -$10.84 million -0.35
Kiora Pharmaceuticals Competitors $3.56 billion $3.18 billion 559.00

Kiora Pharmaceuticals’ competitors have higher revenue and earnings than Kiora Pharmaceuticals. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of current ratings and price targets for Kiora Pharmaceuticals and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kiora Pharmaceuticals 1 0 0 0 1.00
Kiora Pharmaceuticals Competitors 7847 13800 25822 1039 2.41

As a group, “Pharmaceuticals” companies have a potential upside of 25.83%. Given Kiora Pharmaceuticals’ competitors stronger consensus rating and higher possible upside, analysts clearly believe Kiora Pharmaceuticals has less favorable growth aspects than its competitors.

Risk & Volatility

Kiora Pharmaceuticals has a beta of -0.13, suggesting that its stock price is 113% less volatile than the S&P 500. Comparatively, Kiora Pharmaceuticals’ competitors have a beta of -0.05, suggesting that their average stock price is 105% less volatile than the S&P 500.

Insider & Institutional Ownership

77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 0.5% of Kiora Pharmaceuticals shares are owned by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Kiora Pharmaceuticals competitors beat Kiora Pharmaceuticals on 9 of the 12 factors compared.

Kiora Pharmaceuticals Company Profile

(Get Free Report)

Kiora Pharmaceuticals is a clinical-stage biotechnology company focused on developing treatments for retinal and other eye diseases. Its research centers on therapies intended to address conditions with limited treatment options. The company’s pipeline includes KIO-301, an investigational photoswitch designed to restore light sensitivity in people with retinitis pigmentosa and other inherited retinal degenerative diseases. Kiora is also developing KIO-101, an investigational therapy for inflammatory eye diseases, including non-infectious uveitis.

Receive News & Ratings for Kiora Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiora Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.